246 related articles for article (PubMed ID: 7728133)
1. Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation.
Blume KG; Long GD; Negrin RS; Chao NJ; Kusnierz-Glaz C; Amylon MD
Bone Marrow Transplant; 1994; 14 Suppl 4():S9-10. PubMed ID: 7728133
[TBL] [Abstract][Full Text] [Related]
2. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
Long GD; Amylon MD; Stockerl-Goldstein KE; Negrin RS; Chao NJ; Hu WW; Nademanee AP; Snyder DS; Hoppe RT; Vora N; Wong R; Niland J; Reichardt VL; Forman SJ; Blume KG
Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
[TBL] [Abstract][Full Text] [Related]
3. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study.
Blume KG; Kopecky KJ; Henslee-Downey JP; Forman SJ; Stiff PJ; LeMaistre CF; Appelbaum FR
Blood; 1993 Apr; 81(8):2187-93. PubMed ID: 8471778
[TBL] [Abstract][Full Text] [Related]
4. Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
Wu DP; Milpied N; Moreau P; Mechinaud-Lacroix F; Mahe B; Le Tortorec S; Rapp MJ; Bourdin S; Mahe JM; Harousseau JL
Bone Marrow Transplant; 1994 Nov; 14(5):751-7. PubMed ID: 7889008
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
Duerst RE; Horan JT; Liesveld JL; Abboud CN; Zwetsch LM; Senf ES; Constine LS; Raubertas RF; Passarell JA; DiPersio JF
Bone Marrow Transplant; 2000 Mar; 25(5):489-94. PubMed ID: 10713624
[TBL] [Abstract][Full Text] [Related]
6. Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy.
Vaughan WP; Dennison JD; Reed EC; Klassen L; McGuire TR; Sanger WG; Kumar PP; Warkentin PI; Gordon BG; Bierman PJ
Bone Marrow Transplant; 1991 Dec; 8(6):489-95. PubMed ID: 1790429
[TBL] [Abstract][Full Text] [Related]
7. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of etoposide, cyclophosphamide, and total body irradiation in allogeneic bone marrow transplantation for adult patients with hematological malignancies.
Toubai T; Tanaka J; Mori A; Hashino S; Kobayashi S; Ota S; Miura Y; Kato N; Kahata K; Izumiyama K; Yonezumi M; Chiba K; Kondo T; Toyoshima N; Asaka M; Imamura M
Clin Transplant; 2004 Oct; 18(5):552-7. PubMed ID: 15344959
[TBL] [Abstract][Full Text] [Related]
9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
10. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Zander AR; Berger C; Kröger N; Stockshläder M; Krüger W; Horstmann M; Grimm J; Zeller W; Kabisch H; Erttmann R; Schönrock P; Kuse R; Braumann D; Illiger HJ; Fiedler W; de Witt M; Hossfeld KD; Weh HJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
[TBL] [Abstract][Full Text] [Related]
11. Can busulfan replace fractionated total body irradiation as conditioning regimen for allogeneic bone marrow transplantation in children with acute lymphoblastic leukemia.
Wachowiak J; Bettoni C; Lange A; Malicki J; Kaczmarek-Kanold M; Głuszak B; Suchnicki K; Daszkiewicz P; Ebell W
Acta Haematol Pol; 1995; 26(4):377-84. PubMed ID: 8571739
[TBL] [Abstract][Full Text] [Related]
12. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
13. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
Jillella AP; Doria R; Khan K; Zelterman D; Ahmad YH; Smith BR; Holmes W; Becker P; Roberts KB; Rappeport JM
Bone Marrow Transplant; 1999 Jun; 23(11):1095-100. PubMed ID: 10382947
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: lack of superiority over cyclophosphamide-containing conditioning regimens.
Woods WG; Ramsay NK; Weisdorf DJ; Haake R; Vallera DA; Kim TH; Lasky L; Nesbit ME; Bostrom B; Uckun F
Bone Marrow Transplant; 1990 Jul; 6(1):9-16. PubMed ID: 2202462
[TBL] [Abstract][Full Text] [Related]
16. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma.
Stockerl-Goldstein KE; Horning SJ; Negrin RS; Chao NJ; Hu WW; Long GD; Hoppe RT; Amylon MD; Brown BW; Wong RM; Blume KG
Biol Blood Marrow Transplant; 1996 May; 2(2):76-85. PubMed ID: 9118302
[TBL] [Abstract][Full Text] [Related]
17. Treatment of infant leukemia with busulfan, cyclophosphamide +/- etoposide and bone marrow transplantation.
Emminger W; Emminger-Schmidmeier W; Haas OA; Urban C; Ambros P; Peters C; Mann G; Fink FM; Ferstl G; Höcker P
Bone Marrow Transplant; 1992 May; 9(5):313-8. PubMed ID: 1617314
[TBL] [Abstract][Full Text] [Related]
18. Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies.
Crilley P; Lazarus H; Topolsky D; Ciobanu N; Creger RJ; Fox RM; Bulova SI; Shina DC; Gucalp R; Cooper BW
Semin Oncol; 1993 Aug; 20(4 Suppl 4):50-4; quiz 55. PubMed ID: 8342076
[TBL] [Abstract][Full Text] [Related]
19. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]